Celldex Therapeutics, Inc.
CLDXNasdaq
$35.35
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +53.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.4B
Enterprise Value
$1.9B
P/E
—
P/S
2720.4
P/B
5.2
EV/EBITDA
—
PEG
—
FCF Yield
-9.6%
Dividend Yield
—
Revenue (TTM)
$865,000.00
Net Income (TTM)
-$283.6M
Free Cash Flow (TTM)
-$226.2M
Gross Margin
—
Operating Margin
-35729.8%
Net Margin
-32791.4%
ROE
-62.2%
ROIC
-5120.8%
Debt / Equity
—
Net Cash
$451.5M
Return 1Y
+53.9%
Company profile
Celldex Therapeutics, Inc. engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27.
- CEO
- Anthony S. Marucci
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 150
- Headquarters
- New Jersey
- Website
- celldex.com
Management & directors
- Martin Samuel BatesSVP AND CFO
- Pepin RonaldSR. VP & CBO
- Jimenez Freddy A.SVP & GENERAL COUNSEL
Roles derived from SEC Form 4 filings.
Earnings
CLDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15,000.00↓ -97.8%
Diluted EPS-$1.18↑ +45.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$63.4M | -$71.2M | -$115.2M | -$154.5M | -$195.1M | -$287.4M |
| Net income | — | -$70.5M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| Diluted EPS | -$2.02 | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
| Operating cash flow | -$40.4M | -$60.9M | -$103.7M | -$107.3M | -$157.8M | -$210.9M |
| Free cash flow | -$42.0M | -$62.2M | -$105.6M | -$109.1M | -$159.7M | -$213.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -854.1% | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -18599.8% |
| Net margin | — | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -16748.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $3.2M | $1.2M | $695,000.00 | $730,000.00 | $0.00 | $120,000.00 | $15,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$46.3M | -$52.1M | -$56.0M | -$62.7M | -$63.9M | -$73.6M | -$87.2M | -$84.4M |
| Net income | -$35.8M | -$42.1M | -$47.1M | -$53.8M | -$56.6M | -$67.0M | -$81.3M | -$78.7M |
| Diluted EPS | -$0.54 | -$0.64 | -$0.71 | -$0.81 | -$0.85 | -$1.01 | -$1.23 | -$1.18 |
| Operating cash flow | -$29.3M | -$55.3M | -$32.5M | -$54.4M | -$44.0M | -$48.6M | -$63.9M | -$65.6M |
| Free cash flow | -$29.6M | -$55.9M | -$33.2M | -$54.6M | -$44.7M | -$49.1M | -$65.2M | -$67.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1854.2% | -1633.5% | -4768.3% | -9027.2% | -8747.5% | — | -72628.3% | -562900.0% |
| Net margin | -1434.8% | -1320.0% | -4007.8% | -7740.4% | -7753.4% | — | -67764.2% | -524566.7% |
Company news
Jul 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-02 | Martin Samuel Bates· SVP AND CFO | Option exercise | 4,817 | $10.38 | $50,000.46 | filing |
| 2025-12-15 | PEPIN RONALD· SR. VP & CBO | Option exercise | 8,333 | $9.02 | $75,134.49 | filing |
| 2025-12-15 | PEPIN RONALD· SR. VP & CBO | Option exercise | 11,000 | $2.78 | $30,580.00 | filing |
| 2025-12-04 | Jimenez Freddy A.· SVP & GENERAL COUNSEL | Sale | 4,166 | $29.10 | $121,209.77 | filing |
| 2025-11-13 | Wright Richard M. | Sale | 49,298 | $24.00 | $1.2M | filing |
| 2025-11-13 | Wright Richard M. | Option exercise | 15,750 | $22.48 | $354,060.00 | filing |
| 2025-11-13 | Wright Richard M. | Option exercise | 26,672 | $10.38 | $276,855.36 | filing |
| 2025-11-13 | Wright Richard M. | Option exercise | 6,876 | $9.02 | $61,997.45 | filing |
| 2025-08-13 | Jimenez Freddy A.· SVP & GENERAL COUNSEL | Sale | 430 | $25.42 | $10,928.45 | filing |
| 2025-08-13 | Jimenez Freddy A.· SVP & GENERAL COUNSEL | Sale | 341 | $23.95 | $8,167.46 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.